AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty
AnaptysBio filed to dismiss a GSK lawsuit over contract breach claims. The dispute concerns royalties from the cancer drug Jemperli sales.
View signal analysisCompany intelligence
ANAB
AnaptysBio, Inc. · NASDAQ · Healthcare
Price$54.11+0.45% · +$0.24
Market cap1.6BEquity value
P / E-50.1Trailing ratio
Volume436.84KLatest session
Market data
TradingViewANAB price chart
Related signals
1 min delayedLatest ANAB price-moving signals
Browse public ANAB signals with their source context and measured market impact. Open any signal for its permanent analysis page.
GSK and AnaptysBio Embroiled in Legal Battle Over Cancer Drug Rights
AnaptysBio and GSK's Tesaro are engaged in a legal dispute. The lawsuit concerns breaches related to their Jemperli drug partnership. AnaptysBio's shares fell 14% in premarket trading due to the lawsuit. Jemperli's success is crucial for AnaptysBio's financial outlook. Market reaction indicates significant investor concern over AnaptysBio's position.
View signal analysisGSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
GSK's Tesaro files litigation against AnaptysBio for license agreement breaches. A ruling may allow Tesaro to terminate AnaptysBio's dostarlimab license. Dostarlimab is approved in over 35 countries for endometrial cancers. AnaptysBio plans stock repurchase of up to $100 million amid legal issues. ANAB shares dropped 12.37% during premarket trading.
View signal analysisAnaptysBio shares tumble after legal fight with GSK over cancer drug license
AnaptysBio shares dropped 14% amid lawsuits with Tesaro over a partnership breach. Both companies claim breach of partnership in a cancer drug deal.
View signal analysisAnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study
Rosnilimab failed to meet primary efficacy endpoints in ulcerative colitis trial. Phase 2 trial discontinuation may save AnaptysBio over $10 million. Rosnilimab showed safety but low remission rates at Week 12. Future updates on rosnilimab for rheumatoid arthritis expected in H1 2026. Anaptys plans to separate biopharma assets from royalty revenues in 2026.
View signal analysisAnaptysBio Charts Path To Split Into Two Public Companies By 2026
AnaptysBio plans to split into two independent companies. Royalty Management Co will manage substantial royalties from GSK and Vanda. Biopharma Co will focus on therapeutics for autoimmune diseases. Stock surged 28.95% to $30.01 following the announcement. The separation is expected to be completed by the end of 2026.
View signal analysisResearch